These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31327255)

  • 21. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
    Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
    Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates.
    Kolakowski RV; Haelsig KT; Emmerton KK; Leiske CI; Miyamoto JB; Cochran JH; Lyon RP; Senter PD; Jeffrey SC
    Angew Chem Int Ed Engl; 2016 Jul; 55(28):7948-51. PubMed ID: 27198854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer.
    Douez E; Allard-Vannier E; Amar IAM; Jolivet L; Boursin F; Maisonial-Besset A; Witkowski T; Chezal JM; Colas C; Letast S; Auvert E; Denevault-Sabourin C; Aubrey N; Joubert N
    J Control Release; 2024 Feb; 366():567-584. PubMed ID: 38215985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
    Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
    Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates.
    Gandhi AV; Arlotta KJ; Chen HN; Owen SC; Carpenter JF
    J Pharm Sci; 2018 Jul; 107(7):1858-1869. PubMed ID: 29626535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of an Enzymatic Antibody-Drug Conjugation Approach Based on Coenzyme A Analogs.
    Grünewald J; Jin Y; Vance J; Read J; Wang X; Wan Y; Zhou H; Ou W; Klock HE; Peters EC; Uno T; Brock A; Geierstanger BH
    Bioconjug Chem; 2017 Jul; 28(7):1906-1915. PubMed ID: 28590752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
    Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
    Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
    Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH
    Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold.
    Matikonda SS; McLaughlin R; Shrestha P; Lipshultz C; Schnermann MJ
    Bioconjug Chem; 2022 Jul; 33(7):1241-1253. PubMed ID: 35801843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model.
    Waalboer DC; Muns JA; Sijbrandi NJ; Schasfoort RB; Haselberg R; Somsen GW; Houthoff HJ; van Dongen GA
    ChemMedChem; 2015 May; 10(5):797-803. PubMed ID: 25809281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.
    Zhu Z; Ramakrishnan B; Li J; Wang Y; Feng Y; Prabakaran P; Colantonio S; Dyba MA; Qasba PK; Dimitrov DS
    MAbs; 2014; 6(5):1190-200. PubMed ID: 25517304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
    Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
    ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.